Catalent (NYSE:CTLT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a report issued on Monday morning. The firm issued a hold rating on the stock.

CTLT has been the topic of several other reports. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

Shares of CTLT stock opened at $63.48 on Monday. The company’s fifty day simple moving average is $62.42 and its two-hundred day simple moving average is $60.54. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a market cap of $11.52 billion, a P/E ratio of -28.09, a PEG ratio of 2.69 and a beta of 1.15. Catalent has a 52 week low of $41.15 and a 52 week high of $63.50.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.10) earnings per share. Analysts predict that Catalent will post 0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Millennium Management LLC lifted its position in Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the period. Bank of Montreal Can lifted its position in Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after purchasing an additional 1,169,044 shares during the period. National Bank of Canada FI lifted its position in Catalent by 300.0% during the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after purchasing an additional 1,095,578 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after buying an additional 863,624 shares in the last quarter. Finally, ING Groep NV increased its holdings in Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after buying an additional 699,851 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.